- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 31, Issue 9, 2025
Current Pharmaceutical Design - Volume 31, Issue 9, 2025
Volume 31, Issue 9, 2025
-
-
PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment
Authors: Navneet Sharma, Akash Bhati, Shagun Aggarwal, Kamal Shah and Hitesh Kumar DewanganBreast cancer stands on the second position in the world in being common and women happen to have it with high rate of about five-folds around the world. The causes of occurrence can matter with different humans be it external factors or the internal genetic ones. Breast cancer is primarily driven by mutations in the BRCA1 and BRCA2 susceptibility genes. These BC susceptibility genes encode proteins critical for DNA homolo Read More
-
-
-
Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies
Authors: Sina Soleymani, Seyed Morteza Naghib and M.R. MozafariIn recent years, immunotherapy, namely immune checkpoint inhibitor therapy, has significantly transformed the approach to treating various forms of cancer. Simultaneously, the adoption of clinical oncology has been sluggish due to the exorbitant expense of therapy, the adverse effects experienced by patients, and the inconsistency in treatment response among individuals. As a reaction, individualized methods utilizing Read More
-
-
-
Chitosan-grafted Graphene Materials for Drug Delivery in Wound Healing
More LessThe effective and prompt treatment of wounds remains a significant challenge in clinical settings. Consequently, recent investigations have led to the development of a novel wound dressing production designed to expedite the process of wound healing with minimal adverse complications. Chitosan, identified as a natural biopolymer, emerges as an appealing option for fabricating environmentally friendly dressings due to its Read More
-
-
-
Establishment of an Integrated Population Pharmacokinetic/ Pharmacodynamics Model of Apixaban in Chinese Healthy Population Adjusting for Key Genetic Variants
Authors: Guangyan Mu, Yaou Liu, Qiufen Xie, Zhiyan Liu, Hanxu Zhang, Xianmin Meng, Jinfang Song, Zhe Wang, Shuang Zhou, Zining Wang, Kun Hu, Xia Zhao, Maoxing Liao, Jiachun Bao, Qian Xiang and Yimin CuiAimsTo improve the understanding of pharmacokinetic/pharmacodynamic (PK/PD) profiles of apixaban, supporting personalised drug prescriptions for future patients.BackgroundGenetic as well as nongenetic factors can affect the predictable PK and PD characteristics of apixaban.ObjectiveEstablish a integrated popPK/PD model that adjusts for critical genetic variant.MethodsThe integrated PK/PD models Read More
-
-
-
Network Pharmacological Analysis of Hydroxychloroquine Intervention in the Treatment of Iga Nephropathy
Authors: Mengxiao Zou, Gang Xu, Shuwang Ge, Kanglin Guo, Qian Duo and Yichun ChengBackgroundIgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally and has a high propensity to develop into end-stage renal disease (ESRD). Hydroxychloroquine has been proven to reduce proteinuria in IgAN patients, but the precise mechanism remains unclear. Therefore, network pharmacology was used to investigate the mechanism.MethodsPubChem and SwissADME databases were utilized to Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
